866-997-4948(US-Canada Toll Free)

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 595 Pages

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2017, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the bodys immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 30, 28, 3, 110, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 34 and 4 molecules, respectively.

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 7
Type 1 Diabetes (Juvenile Diabetes) - Overview 8
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Development 9
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment 38
Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development 50
Type 1 Diabetes (Juvenile Diabetes) - Drug Profiles 94
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects 549
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products 558
Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones 560
Appendix 569

List of Tables
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2017 34
Number of Products under Development by Companies, H2 2017 36
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 37
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 38
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 39
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 40
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 41
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 42
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 43
Number of Products under Development by Universities/Institutes, H2 2017 44
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 46
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 47
Products under Development by Companies, H2 2017 48
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 49
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 50
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 51
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 52
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 53
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 54
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 55
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 56
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 57
Products under Development by Companies, H2 2017 (Contd..10), H2 2017 58
Products under Development by Companies, H2 2017 (Contd..11), H2 2017 59
Products under Development by Universities/Institutes, H2 2017 60
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 61
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 62
Number of Products by Stage and Target, H2 2017 64
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 65
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 66
Number of Products by Stage and Mechanism of Action, H2 2017 68
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 69
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 70
Number of Products by Stage and Route of Administration, H2 2017 72
Number of Products by Stage and Molecule Type, H2 2017 74
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS, H2 2017 75
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH & Co KG, H2 2017 75
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017 76
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarna Therapeutics BV, H2 2017 76
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AntriaBio Inc, H2 2017 77
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by apceth Biopharma GmbH, H2 2017 77
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aphios Corp, H2 2017 77
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Araim Pharmaceuticals Inc, H2 2017 78
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Arecor Ltd, H2 2017 78
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc, H2 2017 79
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H2 2017 79
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Athersys Inc, H2 2017 80
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC, H2 2017 80
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H2 2017 80
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H2 2017 81
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biocon Ltd, H2 2017 81
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLineRx Ltd, H2 2017 82
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H2 2017 82
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biozeus, H2 2017 83
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc, H2 2017 83
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H2 2017 83
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BTB Pharma AB, H2 2017 84
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences Inc, H2 2017 84
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017 85
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd, H2 2017 85
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 86
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dance Biopharm Inc, H2 2017 86
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DanDrit Biotech A/S, H2 2017 86
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Denceptor Therapeutics Ltd, H2 2017 87
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diabetology (Products) Ltd, H2 2017 87
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diamyd Medical AB, H2 2017 88
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals Inc, H2 2017 88
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DiaVacs Inc, H2 2017 88
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici SpA, H2 2017 89
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Co, H2 2017 89
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ensol Biosciences Inc, H2 2017 90
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by EpiVax Inc, H2 2017 90
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Escape Therapeutics Inc, H2 2017 90
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H2 2017 91
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Fate Therapeutics Inc, H2 2017 92
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H2 2017 92
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GenKyoTex SA, H2 2017 92
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Geropharm LLC, H2 2017 93
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline Plc, H2 2017 93
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 94
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ImmusanT Inc, H2 2017 94
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corp, H2 2017 95
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ixchel Pharma LLC, H2 2017 95
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H2 2017 96
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Just Biotherapeutics Inc, H2 2017 96
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kadimastem Ltd, H2 2017 97
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd, H2 2017 97
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Pvt Ltd, H2 2017 98
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by KPI Therapeutics Inc, H2 2017 98
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals Inc, H2 2017 98
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ligand Pharmaceuticals Inc, H2 2017 99
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MacroGenics Inc, H2 2017 99
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MannKind Corp, H2 2017 100
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Maruho Co Ltd, H2 2017 100
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medestea Research & Production SpA, H2 2017 101
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MedImmune LLC, H2 2017 101
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medtronic Plc, H2 2017 101
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medy-Tox Inc, H2 2017 102
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Melior Discovery Inc, H2 2017 102
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Merck & Co Inc, H2 2017 103
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Meridigen Biotech Co Ltd, H2 2017 103
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 104
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Neovacs SA, H2 2017 104
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Novo Nordisk AS, H2 2017 105
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Oramed Pharmaceuticals Inc, H2 2017 105
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Orgenesis Inc, H2 2017 106
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by OSE Immunotherapeutics, H2 2017 106
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2017 107
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Parvus Therapeutics Inc, H2 2017 107
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pathfinder Cell Therapy Inc, H2 2017 107
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pfizer Inc, H2 2017 108
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaCyte Biotech Inc, H2 2017 108
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaIN Corp, H2 2017 109
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Prometheon Pharma LLC, H2 2017 109
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Purzer Pharmaceutical Co Ltd, H2 2017 109
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by RedHill Biopharma Ltd, H2 2017 110
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by REGiMMUNE Corp, H2 2017 110
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by reMYND NV, H2 2017 111
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Renova Therapeutics Inc, H2 2017 111
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Rubius Therapeutics Inc, H2 2017 111
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sanofi, H2 2017 112
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Semma Therapeutics Inc, H2 2017 112
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sevion Therapeutics Inc, H2 2017 113
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sotio AS, H2 2017 113
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Tetragenetics Inc, H2 2017 113
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Thermalin Diabetes LLC, H2 2017 114
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Toleranzia AB, H2 2017 114
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Topas Therapeutics GmbH, H2 2017 115
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Transgene Biotek Ltd, H2 2017 115
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Traverse Biosciences Inc, H2 2017 115
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by UCB SA, H2 2017 116
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Unicyte AG, H2 2017 116
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViaCyte Inc, H2 2017 117
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by vTv Therapeutics Inc, H2 2017 117
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XERIS Pharmaceuticals Inc, H2 2017 118
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XL-protein GmbH, H2 2017 118
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zealand Pharma AS, H2 2017 118
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2017 574
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2017 (Contd..1), H2 2017 575
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2017 (Contd..2), H2 2017 576
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2017 (Contd..3), H2 2017 577
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2017 (Contd..4), H2 2017 578
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2017 (Contd..5), H2 2017 579
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2017 (Contd..6), H2 2017 580
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2017 (Contd..7), H2 2017 581
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H2 2017 (Contd..8), H2 2017 582
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H2 2017 583
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H2 2017 (Contd..1), H2 2017 584

List of Figures
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2017 34
Number of Products under Development by Companies, H2 2017 35
Number of Products under Development by Universities/Institutes, H2 2017 44
Number of Products by Top 10 Targets, H2 2017 63
Number of Products by Stage and Top 10 Targets, H2 2017 63
Number of Products by Top 10 Mechanism of Actions, H2 2017 67
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 67
Number of Products by Top 10 Routes of Administration, H2 2017 71
Number of Products by Stage and Top 10 Routes of Administration, H2 2017 71
Number of Products by Top 10 Molecule Types, H2 2017 73
Number of Products by Stage and Top 10 Molecule Types, H2 2017 73

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *